BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $114.00

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by Canaccord Genuity Group from $111.00 to $114.00 in a report issued on Monday morning, MarketBeat.com reports. They currently have a buy rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the company. Sanford C. Bernstein decreased their price objective on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Oppenheimer raised their target price on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. The Goldman Sachs Group assumed coverage on shares of BioMarin Pharmaceutical in a report on Monday, May 11th. They issued a “neutral” rating and a $69.00 price target for the company. HC Wainwright upped their price target on shares of BioMarin Pharmaceutical from $50.00 to $60.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $88.00.

Check Out Our Latest Report on BioMarin Pharmaceutical

BioMarin Pharmaceutical Trading Up 1.0%

BMRN opened at $70.24 on Monday. The stock’s fifty day moving average is $59.11 and its two-hundred day moving average is $57.35. The company has a market capitalization of $13.60 billion, a P/E ratio of 189.84, a PEG ratio of 0.48 and a beta of 0.24. BioMarin Pharmaceutical has a 52 week low of $49.26 and a 52 week high of $70.98. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. During the same period in the prior year, the business earned $1.44 EPS. The business’s revenue for the quarter was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts forecast that BioMarin Pharmaceutical will post 4.24 earnings per share for the current year.

Institutional Trading of BioMarin Pharmaceutical

Institutional investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. bought a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth approximately $2,052,000. Evolve Private Wealth LLC purchased a new stake in BioMarin Pharmaceutical during the second quarter valued at approximately $255,000. Landscape Capital Management L.L.C. acquired a new stake in BioMarin Pharmaceutical in the second quarter valued at approximately $320,000. Ieq Capital LLC acquired a new stake in BioMarin Pharmaceutical in the second quarter valued at approximately $11,329,000. Finally, Keating Financial Advisory Services Inc. purchased a new position in BioMarin Pharmaceutical in the second quarter worth $56,000. 98.71% of the stock is currently owned by institutional investors.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: An analyst upgrade helped BioMarin set a new one-year high, signaling improved confidence in the company’s outlook and supporting buying interest. BioMarin Pharmaceutical Sets New 1-Year High After Analyst Upgrade
• Positive Sentiment: Canaccord Genuity reportedly forecasts strong price appreciation for BioMarin, adding to the bullish analyst narrative surrounding the stock. Canaccord Genuity Group Forecasts Strong Price Appreciation for BioMarin Pharmaceutical
• Positive Sentiment: The average Wall Street price target implies approximately 28.2% potential upside. While price targets are imperfect indicators, the article notes that upward earnings-estimate revisions provide a more constructive signal. Wall Street Analysts See a 28.2% Upside in BioMarin
• Positive Sentiment: Zacks identifies BMRN as a top long-term value stock, while a separate comparison evaluates BioMarin favorably against Illumina for investors seeking undervalued medical-biotechnology companies. Why BioMarin Pharmaceutical Is a Top Value Stock for the Long Term BMRN vs. ILMN: Which Stock Is the Better Value Option?
• Neutral Sentiment: BioMarin presented at Canaccord Genuity’s annual growth conference, giving investors additional information about its strategy and growth prospects, but no specific new catalyst was identified in the supplied report. BioMarin Presents at Canaccord Genuity’s Growth Conference
• Neutral Sentiment: The reported short-interest update shows zero shares and zero days to cover, an internally inconsistent figure that appears to reflect a data or reporting issue rather than a meaningful change in positioning.

BioMarin Pharmaceutical Company Profile

(Get Free Report)

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.

Recommended Stories

• Five stocks we like better than BioMarin Pharmaceutical
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
• Legacy Jet Builders Stall While Embraer Accelerates to New Highs